Status:
COMPLETED
Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease
Lead Sponsor:
Ophthalmos Research and Education Institute
Conditions:
Dry AMD
Stargardt Disease 1
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Prospective, randomised, double-blind study to assess the Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (Macular Degeneration Omega-3 S...
Detailed Description
Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries. By the year 2040, the number of people suffering from AMD is estimated to increase by 50%. Stargardt di...
Eligibility Criteria
Inclusion
- Men and women ages from 18 to 85 years old.
- Group 1: For moderate dry macular degeneration the BCVA must be between 50 and 70 (ETDRS) at Screening Visit V1. There must be a large drusen \>125 µm within 1mm from the centre of the fovea. Geographic atrophy can be present but must be \>300 µm away from centre of fovea;
- Group 2: For severe dry macular degeneration the BCVA must be between 41 and 49 (ETDRS) at Screening Visit V1. Geographic atrophy can involve the fovea but must be \<2500 µm in diameter or any size GA but \>200 µm from centre of fovea anywhere;
- Group 3: For moderate Stargardt disease the BCVA must be between 50 and 70 (ETDRS) at Screening Visit V1. The geographic area must be \<2.0 mm in diameter anywhere;
- Group 4: For severe Stargardt disease the BCVA must be between 41 and 49 (ETDRS) at Screening Visit V1. The geographic area must be \<2.5 mm in diameter anywhere;
- Willingness to take the randomised trial investigational product for 6 months;
- Willingness to consent and undergo the examinations/blood testing at the visits;
- Be able to swallow large soft gel capsules;
- Take other supplements as usual; The EPA and DHA intake must be less than 1200 mg/day.
Exclusion
- Any ocular disease in either eye including: Diabetic retinopathy, Central serous retinopathy, Epiretinal membrane, Optic atrophy, Macular hole or pseudohole, Retinal vein occlusion, Amblyopia;
- Previous wet AMD in the study eye;
- Any previous ocular surgery, which may influence progression of dry macular degeneration e.g. trabeculectomy, previous refractive surgery, pterygium surgery. Cataract surgery more than 6 months is not an exclusion criterion unless a complication has occurred during surgery;
- Any topical medication administered for other diseases such as glaucoma. Artificial tears up to 3/day will be allowed;
- Any ocular condition such as allergic conjunctivitis, moderate to severe dry eyes, scleritis, uveitis, keratitis, ocular Herpes Simplex keratitis, ectropion, entropion, ocular surface scaring;
- Any systemic conditions such as gastrointestinal disease e.g. irritable bowel syndrome, Crohn's disease, cancer, etc;
- Any drugs which could affect the eye administered up to 6 months before screening e.g.: Steroids, Ethambutol, Tamoxifen, Chloroquine, Hydroxychloroquine;
- Any condition that would not allow follow up e.g. alcoholism or drug abuse;
- Allergy to any ingredients of the active or placebo pills.
- Pregnant or lactating;
- Current use of EPA/DHA supplements in excess of 1200 mg/day;
- History of liver disease;
- Anti-coagulation therapy such as warfarin/heparin/aspirin/dabigatran/ clopidogrel etc;
- Bleeding tendencies e.g. coagulopathies;
- History of atrial fibrillation;
- Inability to give informed consent (impaired mental capacity e.g. psychiatric deficit);
- Smokers or patients who have not been completely smoke free over the past 5 years.
Key Trial Info
Start Date :
May 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 22 2020
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT03297515
Start Date
May 15 2019
End Date
September 22 2020
Last Update
February 23 2021
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre National d'Ophtalmologie des Quinze-Vingts
Paris, France
2
Department of Ophthalmology, Justus-Liebig-University-Giessen
Giessen, Germany
3
Università degli Studi G. d'Annunzio Chieti-Pescara
Chieti, Italy
4
ASST Santi Paolo e Carlo
Milan, Italy